--- title: 'Morning Brief — Friday, October 9, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-10-09' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-10-09' audio: 'https://media.doc.social/podcasts/morning-brief/2026-10-09.mp3' --- # Morning Brief — Friday, October 9, 2026 CMS posts the CJR-X participant list: 2,217 hospitals in a mandatory 90-day hip, knee and ankle bundle starting January 1, 2028 · SurGenTec takes an exclusive license to Allevion Medical's Vantage, a fully disposable lumbar decompression kit cleared in March as K252546 · FDA 510(k) clears Mass General's GSPE Spacer, a gentamicin-loaded UHMWPE temporary knee spacer for two-stage PJI; commercial… ## Summary 4 stories this morning, for surgeons and the people who support them. - **CMS posts the CJR-X participant list: 2,217 hospitals in a mandatory 90-day hip, knee and ankle bundle starting January 1, 2028** — CMS Innovation Center CJR-X model page (verified 2026-10-08): hospitals on the participant list must submit the Primary Point of Contact Identification Form naming two contacts. CJR-X was finalized in the FY 2027 IPPS final rule and is mandatory nationwide beginning January 1, 2028; first nationwide test of a mandatory episode-based payment model. Original CJR ran in 34 MSAs and ended December 31, 2024; PY6-7 (2021-2023) evaluation estimated $112.7 million in net savings while maintaining quality. Episode: procedure through 90 days after discharge, nearly all related Part A and B items; providers still paid FFS during the year, then reconciliation vs a hospital target price, with a quality floor (composite of THA/TKA RSCR, OP-36, HCAHPS, OAS CAHPS, THA/TKA PRO-PM) before reconciliation payments. Included triggers: MS-DRG 469 (major hip/knee with MCC or total ankle), 470 (without MCC), 521/522 (hip replacement with hip-fracture PDX, with/without MCC), HCPCS 27447 (TKA) and 27130 (THA) in the hospital outpatient setting. Exemptions: TEAM participants, Maryland hospitals, hospitals not paid under both IPPS and OPPS (critical access and rural emergency hospitals). TEAM is 30 days and also covers non-LEJR (including spinal fusion); TEAM hospitals join CJR-X when TEAM ends. Participant list xlsx (https://www.cms.gov/priorities/innovation/files/cjrx-participant-list.xlsx): 'Acute care hospitals, as of September 30, 2026, identified by CCN, that satisfy the CJR-X participant definition, as defined in 42 CFR 512.605'; 2,217 unique 6-digit CCNs counted from shared strings. Second source: AHA News, Oct 6, 2026 (https://www.aha.org/news/headline/2026-10-06-cms-releases-list-participants-cjr-x-payment-model-joint-replacement-procedures). CMS July 31, 2026 press release for the final-rule announcement (https://www.cms.gov/newsroom/press-releases/cms-news-cms-announces-nationwide-expansion-proven-joint-replacement-program). No prior Morning Brief coverage of CJR-X or the participant list (grep of drafts). [Source](https://www.cms.gov/priorities/innovation/innovation-models/cjr-x) - **SurGenTec takes an exclusive license to Allevion Medical's Vantage, a fully disposable lumbar decompression kit cleared in March as K252546** — SurGenTec (Boca Raton, privately held) announced Oct 8, 2026 an exclusive license to Allevion Medical's patented Vantage spinal decompression technology. Verified against the Business Wire text via Yahoo Finance reprint (https://finance.yahoo.com/healthcare/articles/surgentec-enters-exclusive-license-agreement-150000588.html): fully disposable, sterile system for MIS lumbar decompression; laminotomy or laminectomy with direct visualization; targets hypertrophic bone at lamina and facet contributing to lumbar stenosis; workflow described as locate/visualize/decompress; single-use integrated illumination; depth-controlled bone resection; no additional instruments or sterile processing. Quote from Matt Marta, VP of Sales. Portfolio context from the same release: facet fixation, synthetic biologics, bone graft delivery, SI fusion. Terms (price, duration, territory) not disclosed. FDA 510(k) database: K252546, VantageTM Lumbar Decompression Kit, Allevion Medical LLC, 915 Clint Moore Rd, Boca Raton FL 33487; received Aug 12, 2025, decision Mar 12, 2026, SESE, product code HRX (arthroscope), subsequent HAE, 21 CFR 888.1100, traditional. Second source: Orthopedics This Week / OrthoSpineNews Oct 8, 2026. No prior Morning Brief coverage of SurGenTec, Allevion or Vantage as a decompression kit (grep; unrelated 'Vantage' hits were Medicare Advantage). [Source](https://www.businesswire.com/news/home/20261008415681/en/SurGenTec-Enters-Exclusive-License-Agreement-with-Allevion-Medical-for-Vantage-Spinal-Decompression-System) - **FDA 510(k) clears Mass General's GSPE Spacer, a gentamicin-loaded UHMWPE temporary knee spacer for two-stage PJI; commercial license still pending** — FDA 510(k) database: K260063, GSPE Spacer, applicant The General Hospital Corporation d/b/a Massachusetts General Hospital, MGB Innovation, Somerville MA; applicant contact Orhun Muratoglu; correspondent Mcra LLC / Hollace Rhodes. Device classification: prosthesis, knee, patellofemorotibial, semi-constrained, cemented, polymer/metal/polymer; regulation 888.3560; product code JWH, subsequent MBB; received Jan 8, 2026, decision Sep 11, 2026, SESE, traditional, combination product yes. Mass General Brigham news (https://news.massgeneralbrigham.org/en/antibiotic-delivery-system-for-knee-replacement-infections): gentamicin incorporated into UHMWPE temporary knee spacer for PJI after implant removal, load-bearing during the interval to reimplantation; intended to address limited support and inconsistent elution of antibiotic bone-cement spacers; 2025 JBJS paper from the Harris lab reported very small gentamicin particles produced higher, more sustained release while preserving more than 90% of the polymer's original mechanical strength; team Orhun K. Muratoglu, Ebru Oral, Mehmet Asik; MGB Innovation is in the process of licensing IP to a large implant manufacturer (unnamed). Infection after ~2% of knee replacements (institution figure in the release). No commercial brand, manufacturer or launch date in the announcement. No prior coverage of GSPE, Muratoglu spacer or gentamicin polyethylene spacer (grep). [Source](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K260063) - **JBJS Yale RCT in primary THA: anterior QLB plus LFCN block vs periarticular/local infiltration, both with dual glucocorticoids, no difference in day-one opioids** — Li J, Rubin LE, Krishnan R, Blessing M, Townsend D, Tung WS, Zhao X, Treggiari M, He Z, Dai F. J Bone Joint Surg Am, 2026 Oct 7, doi 10.2106/JBJS.25.01476, PMID 42127167. Verified against the PubMed abstract via NCBI E-utilities. Single-center RCT (Yale per OrthoBuzz commentary 2026-10-08; abstract itself does not name the site, so the script does not claim Yale). 192 randomized, 188 analyzed (93 aQLB+LFCNB, 95 PALIA); mean age 61, 46% male. Both arms: 60 mL 0.2% ropivacaine, 10 mg dexamethasone sodium phosphate, 80 mg methylprednisolone acetate. Primary outcome POD1 oral morphine milligram equivalents: median 29.84 (IQR 17.72-38.75) vs 30.50 (18.00-42.00), p=0.57. Secondary: no differences in POD2 opioids, BPI, AMPAC, PROMIS through 1 year, LOS; fasting serum glucose POD1 lower in block group 141.50 vs 153.00 mg/dL, p=0.003. Conclusion: no significant differences in daily opioid consumption, pain score, or functional recovery. Level II. Script does not use OrthoBuzz extras (50-to-15 tablet cut, cost claims) because they are not in the abstract. No prior coverage of this trial (grep PALIA, quadratus lumborum). [Source](https://pubmed.ncbi.nlm.nih.gov/42127167/) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._